Background: Endometrial carcinoma is a predominant health problem for women worldwide. However, there is a lack of data on genetic mutation frequencies in endometrial cancer patients of different ethnicities and tumor grades. Objective: The objective of this study is to provide data regarding mutation frequencies in endometrial cancer patients of different ethnic groups and tumor grades by analyzing large-scale cancer genomic datasets of a database.
INTRODUCTION
Endometrial cancer is the most common gynecological cancer in the United States. According to the American Cancer Society, in 2018, there would be 63,230 new cases of endometrial cancer, and about 11,350 patients will die from this cancer. [1, 2] In fact, endometrial cancer is a predominant health problem for women worldwide. [3] In women from developed countries, endometrial cancer is usually detected after the age of 60 years. [4] Nearly 90% of the diagnosed cases are sporadic, while 10% are attributed to genetic factors. [5] Endometrial cancer is a multifactorial disease. Obesity and long-term therapeutic administration of estrogen are the most common risk factors, while pathological production of estrogen has also found to be associated. [6] [7] [8] [9] In addition, nulliparity and infertility are among factors that increase the risk of endometrial cancer. [10] Endometrial cancer is classified into Type I or Type II, based on clinical and pathological differences. Type I endometrial cancer accounts for 80% of all cases and is linked to excess estrogen exposure. It is associated with low-grade tumors and has a good prognosis. [11, 12] Type II accounts for 20% of all new cases of endometrial cancer and is a highly differentiated papillary serous-cell carcinoma that is not linked to estrogen exposure. It is commonly detected at later stages and is associated with poor prognosis. [11] Genetic mutations in cancers have been shown to be influenced by patients' ethnicity and grade of tumor. [13] [14] [15] [16] [17] [18] [19] [20] These variations in mutations affect therapeutic regimes. [21] [22] [23] [24] Conceptually, precision medicine requires knowledge of the exact mutation present in each patient along with the tumor stage. Currently, there is a lack of data regarding genetic mutation frequencies (GMFs) in endometrial cancer patients of different ethnic groups and tumor grades. To obtain significant data regarding any such differences in mutation frequencies, a large-scale, multicenter study that includes endometrial cancer patients with different ethnicities and tumor stages is required. However, such studies are difficult to conduct and require concerted efforts at several levels. Nonetheless, an analytical study of large-scale endometrial cancer genomics datasets can provide initial data on GMFs of different ethnic groups and tumor grades. Accordingly, this study was conducted using cBioPortal, an open source database of large-scale cancer genomics data sets, to search for variability in genetic mutations of endometrial cancer in different ethnic groups and stages. 
MATERIALS AND METHODS

Data collection
Data analysis
To assess the GMF of different ethnicities, the Uterine Corpus Endometrial Carcinoma (TCGA, PanCancer Atlas) database was used through cBioPortal. [25] For GMFs of different grades, information was obtained from the Uterine Corpus Endometrial Carcinoma (TCGA, Nature 2013) database. [26] Finally, the Kaplan-Meier method was used to determine the survival rates of endometrial cancer patients in the GDC Data Portal database of cBioPortal. [27] The frequencies of genetic mutations were then normalized to the total patient number in each group using Microsoft Excel for Mac 2011. Using Prism 7 for Mac software (GraphPad Software, La Jolla, CA, USA), a heat plot of the genes most frequently mutated was generated for each ethnic group and grouped for analysis of different tumor stages.
Ethical issues
This work used anonymous, open-access data, and thus did not involve any personal information of individuals.
RESULTS
Mutation frequency by ethnicity
To explore the variation in the frequency of endometrial cancer-associated genetic mutations among different ethnicities, a hotspot model was used. As shown in Figure 1 , there was a clear variation in the GFM between individual genes. The PTEN gene showed nearly identical mutation frequencies in White, Asian and American Indian or Asian Native endometrial cancer patients, but Black/African American patients possessed a lower mutation frequency. PIK3CA displayed high mutation frequency in Asians compared with other ethnicities. However, mutations were less frequent in Asians compared to other ethnic groups. CTNNB1 and RYR1 mutation were found more frequently in Native Hawaiian or other Pacific Islanders compared with other ethnic groups. FAT1 exhibited a high mutation frequency in Black/African American and Asian populations; FAT4 mutations were more frequent in Asians; MUC5B mutations occurred more frequent in American Indian or Asian Native; while ZFHX4 and FLG were more frequently mutated in Asians. TP53 and RYR2 mutation frequencies were very high in Black/African American and Native Hawaiian or Other Pacific Islander, respectively, compared with other ethnicities. TNN mutation frequencies were high in all ethnicities, except among Asian patients, in whom it was very low.
Mutation frequency by endometrial carcinoma stage
To study the distinct mutation frequencies in each stage of endometrial cancer, the author compared the GMFs of 18 genes that were found to be most commonly mutated in endometrial cancer patients [ Figure 2 ]. All genes, except TP53 and POLQ, showed high mutation frequencies in the first stage of the cancer. The PTEN, PPP2R1A and ARID1A genes were less frequently mutated in the second stage of cancer than the other genes studied. The third stage of the cancer exhibited the most frequent genetic mutations, with TP53, POLQ, PPP2R1A, NEB, RYR2 and ERCC6 L2 displaying the highest mutation frequencies. In the fourth stage, mutation frequencies were much lower than that in the other stages of endometrial cancer.
Survival rates
With regards to the potential prognostic value of the mutated genes in endometrial cancer, it was found that patients with mutations in PIK3CA and ARID1A have a significantly better prognosis than patients with the wild-type gene (P < 0.05). Similarly, patients with mutations in PTEN, KRAS, TNN, CTNNB1 and MUC16 had a better prognosis than patients with the wild-type genes [ Figure 3 ], although this finding is not significant (P > 0.05). However, patients with a mutation in CSMD3 did not have any prognostic difference from patients with its wild-type counterpart. In contrast, patients with the wild-type TP53 and PIK3R1 genes displayed a better prognosis relative to patients with mutations in these genes. 
DISCUSSION
Genetic mutations in cancers are likely to be influenced by patients' ethnicity and grade of tumor. [13] [14] [15] [16] [17] [18] [19] [20] However, there is a lack of knowledge on GMFs in endometrial cancer patients of different ethnic groups. The current analytical study found that GMFs in endometrial cancer patients vary by ethnicity. Variations in GMFs can help understand biological differences between ethnic groups, which in turn could be used for targeted therapy. Further, this study also demonstrates altered activity of certain genes during different cancer stages.
In African Americans with prostate cancer, recurrent loss-of-function mutations has been shown in the ERF gene, which is a tumor suppressor gene. [28] Increased mutations in KRAS have been reported in African Americans with colon cancer compared with Caucasians patients. [29] In non-small cell lung cancer, Black women have been found to be at a higher risk of EGFR mutations than White women. [30] BRCA1 mutations in breast cancer patients have been shown to be more prevalent in Hispanics compared with other ethnicities. [15] Further, BRCA1 exon 2 mutations are more frequent in Ashkenazi Jewish women relative to Caucasians. [31] Such differences in GMFs between women of different ethnicities were also observed in several other studies. [32] [33] [34] These and the current study results collectively show that genetic mutations vary by ethnicity, and thus could potentially be used to determine and administer precise therapy for a subset of patients within an ethnic group. Therefore, a larger study, including more ethnic groups, could potentially aid in improving endometrial cancer diagnosis and therapy.
The current study also demonstrated differences in the mutation frequency between endometrial cancer stages, which could potentially be used to better understand the progression of cancer and to monitor its treatment. The frequent mutation of PTEN in early-stage endometrial cancer has also been suggested previously. [35] However, in that study, endometrial carcinoma PTEN mutations were compared with that of endometrial hyperplasia, thereby limiting the validity of the finding. Therefore, a large population study should be conducted to elucidate the genetic mutation patterns in each stage of endometrial cancer. This would further contribute to the implementation of precise therapy. Previously, in studies of other cancers, GMFs have been found to vary in different stages of cancer. [36] [37] [38] [39] [40] However, to the best of the author's knowledge, this is the first study demonstrating GMF variation in different stages of endometrial carcinoma.
Endometrial carcinoma is characterized by mutations in many genes, with microsatellite instability genes PTEN, KRAS, PIK3CA and -catenin most commonly involved. [19, [41] [42] [43] The mechanisms that initiate and drive endometrial cancer have been explored. Mutations in the pro-survival genes, such as KRAS, Akt, mTOR and -catenin, or pro-apoptotic genes, such as PTEN and p53, have all exhibited a role in the pathological findings of this cancer. [44] [45] [46] Understanding the molecular background of uterine cancers could help in determining future therapy for endometrial cancer. [44] [45] [46] Small molecules capable of targeting and inhibiting these genes have been found to potentially reduce mortality rates of endometrial cancer patients. [45] Further, inhibitors can be combined with hormonal or cytotoxic agents, thereby focusing on multiple targets. [46] For example, the PI3K/AKT/mTOR pathways have been used for uterine cancer therapy. [12, 47] In fact, the effectiveness of mTOR inhibitors such as AZD8055, OSI-027 and INK128 for treating endometrial cancer are being evaluated in clinical trials. [48] Other inhibitors have also been tested in vivo but have not yet been introduced into trials. [46] The results of this study's survival rates of patients could potentially be used as prognostic markers for clinical outcome. This study found that mutations in TP53 and PIK3R1 are correlated with poor prognosis in endometrial cancer. These results conform to the findings of previous study results on other cancers. For example, TP53 has been shown to correlate with poor prognosis in breast cancer, [49, 50] lymphoma, [51] colon cancer, [52] lung cancer [53] and leukemia, [54] while PIK3R1 is associated with poor prognosis in glioblastoma. [55] In patients with late-stage endometrial cancer, poor prognosis may be related to the observed increased frequency of TP53 mutations.
It should be noted that because the current study is a retrospective study that is more exploratory and hypothesis generating in nature, its findings cannot be considered conclusive. Therefore, future work should comprise large sample sizes, including more ethnic groups such as Arabs from different countries, and long-term follow-up, including detailed information on patient body weight, morbidity, mortality and treatment regimens administered.
CONCLUSION
The findings of the current retrospective study illustrate a new GMF profile for endometrial cancer patients of different ethnicities. Further, this study demonstrates the altered activity of certain genes during different cancer stages and that the survival rates of patients with endometrial carcinoma could be predicted using the set of genes investigated. Nonetheless, to validate the findings of this study, future prospective studies should be conducted with large sample sizes, more diverse ethnic groups and long-term follow-up.
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